Mental health and non-drug digital treatments provider Big Health has acquired digital therapeutic developer Limbix for an undisclosed sum.
Established in 2016, Limbix is claimed to have developed the first evidence-based digital therapeutic for teens and young adults with depression symptoms.
Go deeper with GlobalData
Through its Series A funding round, the company raised $30m and developed a research-based pipeline of adolescent products.
Limbix has developed a digital therapeutic called SparkRx to provide a neurobehavioral intervention (cognitive behavioural therapy (CBT) – behavioural activation) for patients aged between 13 and 22 years as an adjunct treatment for depression symptoms.
Supported by trial data showing a clinically meaningful reduction in depression symptoms, the self-guided CBT-based treatment is intended to teach skills such as mindfulness, problem-solving, behavioural activation and mood tracking.
The US Food and Drug Administration has not granted clearance or approval for SparkRx.
Big Health CEO and executive chairman Arun Gupta said: “We must continue to rise to the challenge of the mental health crisis – our acquisition of Limbix is a strategic milestone in advancing our mission to help millions back to good mental health.
“Our portfolio of evidence-based, clinically validated digital treatments will enable a record number of adult and adolescent patients to get immediate access to safe and effective non-drug options.”
Big Health provides a number of mental health treatments and therapies, including the Sleepio and Daylight programmes for insomnia and anxiety treatments, respectively.
